Self-assembled nanoparticles of cholesterol-modified O-carboxymethyl chitosan as a novel carrier for paclitaxel by Wang, Y. S. et al.
This content has been downloaded from IOPscience. Please scroll down to see the full text.
Download details:
IP Address: 59.77.43.191
This content was downloaded on 12/07/2015 at 06:44
Please note that terms and conditions apply.
Self-assembled nanoparticles of cholesterol-modified O-carboxymethyl chitosan as a novel
carrier for paclitaxel
View the table of contents for this issue, or go to the journal homepage for more
2008 Nanotechnology 19 145101
(http://iopscience.iop.org/0957-4484/19/14/145101)
Home Search Collections Journals About Contact us My IOPscience
IOP PUBLISHING NANOTECHNOLOGY
Nanotechnology 19 (2008) 145101 (8pp) doi:10.1088/0957-4484/19/14/145101
Self-assembled nanoparticles of
cholesterol-modified O-carboxymethyl
chitosan as a novel carrier for paclitaxel
Yin-song Wang1,4, Qian Jiang2,4, Rong-shan Li1, Ling-long Liu2,
Qi-qing Zhang2,3,5, Yu-mei Wang1 and Jing Zhao1
1 College of Pharmacy, Tianjin Medical University, No. 22 Qixiangtai Road, Heping District,
Tianjin 300070, People’s Republic of China
2 Institute of Biomedical Engineering, Chinese Academy of Medical Science,
Peking Union Medical College, PO Box 25(204), Tianjin 300192, People’s Republic of China
3 Research Center of Biomedical Engineering Medical School, Xiamen University,
168 DaXue Road, Xiamen 361005, People’s Republic of China
E-mail: wangyinsong@tijmu.edu.cn and zhangqiq@xmu.edu.cn
Received 29 November 2007, in final form 15 January 2008
Published 4 March 2008
Online at stacks.iop.org/Nano/19/145101
Abstract
Self-assembled nanoparticles of cholesterol-modified O-carboxymethyl chitosan (CCMC) were
prepared to be used as a novel carrier for paclitaxel (PTX) in this study. CCMC-6.9 was
synthesized by the covalent conjugation of cholesterol to O-carboxymethyl chitosan with the
succinyl linkage and the degree of substitution (DS) of the cholesterol moiety was 6.9%.
CCMC-6.9 formed self-assembled nanoparticles with a size of 209.5 nm in aqueous media.
Paclitaxel-loaded CCMC-6.9 self-assembled nanoparticles were prepared using a dialysis
method and their characteristics were analyzed by dynamic laser light scattering (LLS),
transmission electron microscopy (TEM) and ultraviolet spectroscopy (UV). PTX-loaded
CCMC-6.9 self-assembled nanoparticles were almost spherical in shape and their size increased
from 245.6 to 355.3 nm with PTX-loading content increasing from 18.7% to 34.9%. In vitro
release of PTX from CCMC-6.9 self-assembled nanoparticles was carried out by the dynamic
dialysis method. PTX continuously released in phosphate buffered saline (PBS) solutions for
84 h at 37 ◦C and its release was sensitive to the pH of the release media. The biodistribution of
PTX-loaded CCMC-6.9 self-assembled nanoparticles was studied in female Balb/c mice.
Compared with PTX in the solution of Cremophor EL (polyethoxylated castor oil)/ethanol
(PTX-Cre), CCMC-6.9 self-assembled nanoparticles significantly increased the uptake of PTX
in plasma, liver and spleen, but decreased the uptake in heart and kidney. These results suggest
that CCMC-6.9 self-assembled nanoparticles can effectively solubilize PTX and modify its
tissue biodistribution, which may be advantageous in enhancing the therapeutic index and
reducing the toxicity of PTX.
1. Introduction
Polymeric amphiphiles consisting of hydrophilic and hy-
drophobic segments can form nanosized self-assemblies with
a hydrophobic core and a hydrophilic shell due to the intra-
4 Contributed equally to this work.
5 Address for correspondence: PO Box 25(204), Tianjin 300192,
People’s Republic of China.
and/or intermolecular interactions of hydrophobic segments in
the aqueous media [1, 2]. Many investigations [3–7] have
reported that these self-assemblies, used as the drug deliv-
ery system, can reduce the unwanted toxic side effects, pro-
long the circulation time, reduce the uptake by the reticuloen-
dothelial system (RES) and enhance the therapeutic index of
drugs. Hydrophobically modified polysaccharides, as a novel
kind of polymeric amphiphiles, have attracted an increasing
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Figure 1. Chemical structure of cholesterol-modified O-carboxylmethyl chitosan (CCMC).
interest recently [8, 9] since their self-assembled nanoparti-
cles in the aqueous media are suitable for trapping hydropho-
bic substances [10] and some bioactive macromolecules [11]
in biotechnology and medicine.
Chitosan, a homopolymer of (1, 4)-linked 2-amino-2-
deoxy-β-glucan, is produced by deacetylation of chitin, which
is the second most abundant and renewable natural polysac-
charide after cellulose. Since chitosan shows many good prop-
erties such as biocompatibility, biodegradability, positively
charged, nontoxicity and bioadhesivity, it can be used as an
ideal biomedical material [12, 13]. Hydrophobically modified
chitosan derivatives such as alkylated chitosan [14, 15] and
deoxycholic acid-modified chitosan [16, 17] have been focus-
ing on recently due to their strong amphiphilic property and
their formation of self-assembled nanoparticles in the aqueous
media, which is very useful for biotechnological and pharma-
ceutical applications. We have previously reported the syn-
thesis and characteristics of self-assembled nanoparticles of
cholesterol-modified O-carboxymethyl chitosan (CCMC, fig-
ure 1) [18] and their interaction with bovine serum albumin
(BSA) [19]. In addition, the hydrophobic core of these self-
assembled nanoparticles formed by the hydrophobic interac-
tions among the cholesterol moieties was also considered to
act as a reservoir of hydrophobic substances. In this study,
paclitaxel (PTX) was chosen as a model drug to assess the po-
tential of CCMC self-assembled nanoparticles as a carrier for
hydrophobic anticancer drugs by the in vitro and in vivo inves-
tigations.
PTX is known to have highly effective activity against
various tumors and has been used clinically in the treatment
of metastatic breast cancer, ovarian cancer and several other
malignancies [20, 21]. Because the water solubility of PTX is
very low, the commercial preparation of PTX is formulated in
a solution composed of a 50:50 (v/v) mixture of Cremophor
EL (polyethoxylated castor oil) and dehydrated alcohol, which
is diluted 5–20 fold in normal saline or dextrose solution (5%)
before administration. However, serious side effects, such as
hypersensitivity reactions, nephrotoxicity and neurotoxicity,
attributable to Cremophor EL have been reported [22, 23].
Therefore, CCMC-6.9 self-assembled nanoparticles, being
used as a carrier, was hoped to increase the aqueous solubility,




Cholesterol-modified O-carboxymethyl chitosan (CCMC-6.9)
was synthesized and analyzed according to the method
previously reported [18]. Briefly, the cholesterol moiety was
conjugated to O-carboxymethyl chitosan (CMC, molecular
weight was 6.78 × 104 Daltons and DS of carboxymethyl
groups was 70%) by the succinyl linkage. The degree
of substitution (DS) of cholesterol moiety, defined as the
number of cholesterol moieties per 100 glucosamine units of
chitosan, was 6.9%. Paclitaxel (PTX) was obtained from
Xian Tiancheng Drugs & Bioengineering Co., Ltd (China).
Cremophor EL was obtained from BASF Corp (Parsippany,
NJ). Pyrene was obtained from Aldrich and purified by
recrystallization from absolute ethanol. All reagents for
high performance liquid chromatography (HPLC) analysis,
including acetonitrile and methanol, were HPLC grade. Other
chemical reagents in the study were analytical grade.
Six to eight-week-old female Balb/c mice were supplied
by the Laboratory Animal Center of Tianjin Medical
University, (Tianjin, China). The animals were used
following the guidelines of the Ethical Committee for Animal
Experiments of Tianjin Medical University. The animals were
acclimatized at a temperature of 25 ± 2 ◦C and a relative
humidity of 70% ± 5% under natural light/dark conditions for
at least 24 h before dosing.
2.2. Preparation of CCMC-6.9 self-assembled nanoparticles
and drug loading
CCMC-6.9 self-assembled nanoparticles were prepared by the
method previously reported [18, 19]. Briefly, CCMC-6.9 was
dispersed in distilled water under gentle shaking at 37 ◦C
for 48 h, followed by sonication using a probe type sonifier
(Automatic Ultrasonic Processor UH-500A, China) at 100 W
for 2 min. The sonication step was repeated three times until
the desired size value had been reached. To prevent the sample
solution from heat built-up during the sonication, the pulse
function was used (pulse on 2.0 s, pulse off 2.0 s).
PTX-loaded CCMC-6.9 self-assembled nanoparticles
were prepared by a dialysis method [24]. Briefly, the
different amounts of PTX dissolved in methanol were slowly
added to CCMC-6.9 self-aggregated nanoparticle solutions
2
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under stirring, and then the methanol solvent was removed
by dialysis (Millipore dialysis tube, molecular weight cutoff
12–14 kDa, USA) to obtain PTX-loaded CCMC-6.9 self-
assembled nanoparticles. The dust and impurity in the sample
solution were removed by passing through a filter (0.45 μm,
Millipore).
2.3. Characterization of PTX-loaded CCMC-6.9
self-assembled nanoparticles
The mean diameter and particle size distribution of CCMC-6.9
self-assembled nanoparticles with/without PTX loading were
determined by laser light scattering (LLS) with a Brookhaven
BI-200SM/BI-9000AT goniometer (USA) at a scattering angle
of 90◦, a wavelength of 532 nm and a temperature of 25 ±
0.1 ◦C.
The morphology of CCMC-6.9 self-assembled nanoparti-
cles with/without PTX loading was observed by transmission
electron microscopy (TEM). In practice, the sample solution
was dropped onto the carbon-coated 200 mesh copper grid.
Then, the grid was air-dried and imaged using a Tecnai G2 20
S-Twin TEM (FEI Company, USA) at 80 kV.
2.4. Determining the loading capacity of PTX
The loading capacity of PTX was determined according to the
method proposed by Huo MR [25]. To calculate the drug
loading content (drug/carrier) and the drug loading efficiency
(loaded drug/initially added drug), PTX-loaded CCMC-6.9
self-assembled nanoparticles were dispersed in methanol, and
then the UV absorption of PTX at the wavelength (λ) of
227 nm was measured with a Beckman DUR 640 UV
spectrophotometer (USA).
2.5. PTX releases from CCMC-6.9 self-assembled
nanoparticles in vitro
PTX release behavior was studied in vitro by the dynamic
dialysis method reported by Han [26] in phosphate buffered
saline (PBS) solution with pH values of 4.0, 7.2 and 9.0,
respectively. Briefly, the solutions of PTX-loaded CCMC-
6.9 self-assembled nanoparticles were respectively placed into
Visking dialysis tubing (molecular weight cutoff 12–14 kDa,
Millipore, USA) and dialyzed against 50 ml of the above PBS
solutions at 37 ± 0.2 ◦C in an air-bath shaker at 50 rpm. Then,
0.5 ml of the release media was collected and replaced with
an equal volume of the fresh release media at predefined time
intervals. The release amounts of PTX were determined by
the high performance liquid chromatography (HPLC) method
described below. PTX release from the solution of Cremophor
EL/dehydrated alcohol (50/50 v/v) was also conducted under
the same conditions as the control.
2.6. Tissue biodistribution study
Female Balb/c mice were administered either PTX-loaded
CCMC-6.9 self-assembled nanoparticles or PTX in the
Cremophor EL/ethanol solution (PTX-Cre) at a single dose of
5 mg PTX/kg via the tail vein. At 0.083, 0.25, 0.5, 1, 2, 4,
8 and 12 h after drug injection, each animal (n = 6 for each
time point) was killed and heart, liver, spleen, lung and kidney
as well as blood samples were collected. Tissue samples were
washed in ice-cold saline, blotted with paper towels to remove
excess fluid, weighed and stored at −50 ◦C until assessed for
drug concentration by HPLC.
2.7. HPLC analysis
The analyses of PTX levels in vitro and in vivo were carried
out using a HPLC system consisted of a LC-10ATVP pump, a
manual injector with a 20 μl fixed loop and a SPD-10AVP UV–
vis detector (Shimadzu, Kyoto, Japan) at 227 nm. A reversed-
phase column (Lichrospher C18, 4.6 mm × 150 mm, 5 μm,
Merck, Darmstadt, Germany) was used at room temperature
and 20 μl samples were injected into this column for all
the analyses. The mobile phase consisted of methanol,
acetonitrile and water (25:35:40, v/v/v) and its flow rate was
1.0 ml min−1. The retention time of PTX was approximately
13.2 min.
Tissue samples were homogenized in the mixed solution
of acetonitrile and water (50:50 v/v). 50 μl diazepam
(1 μg ml−1) as an internal standard was added into 200 μl of
plasma or tissue samples, and vortexed for 1 min. The drug and
the internal standard were then extracted into 4 ml of tert-butyl
methyl ether by vortex mixing for 5 min. After centrifugation
at 6000g for 10 min, 3 ml of the clear supernatant was removed
and evaporated under a gentle stream of nitrogen. The residue
was then dissolved in 200 μl mobile phase and centrifuged at
10 000g for 5 min before HPLC analysis.
2.8. Statistical evaluation
The area under the curve (AUC) based on statistical moment
theory was calculated by the trapezoid method. The results
were presented as means with standard deviations (SD) and
were analyzed for statistical significance by Student’s t-test.
The level of significance was defined at p < 0.05.
3. Results and discussion
3.1. Preparation of CCMC-6.9 self-assembled nanoparticles
and drug loading
CCMC-6.9 formed monodisperse self-assembled nanoparticles
with a relatively narrow size distribution by probe sonication
in distilled water. The mean diameter of these nanoparticles
determined by the dynamic laser light scattering (LLS) was
209.5±0.6 nm, and the polydispersity index was 0.165±0.031
(figure 2(b)). The TEM image (figure 2(a)) shows that CCMC-
6.9 self-assembled nanoparticles were regular spherical in
shape and the size was slightly smaller than the size determined
by LLS. This is mainly due to the process involved in the
preparation of the sample. TEM depicted the size in the dried
state of the sample, whereas LLS measured the size in the
hydrated state of the sample, so that the size measured by LLS
was a hydrodynamic diameter and had a larger value because
of the solvent effect [18, 27].
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Figure 2. TEM image (a) and the size distribution (b) of CCMC-6.9 self-assembled nanoparticles in distilled water. The concentration of
CCMC-6.9 was 0.5 mg ml−1.
Figure 3. TEM image (a) and the size distribution (b) of PTX-loaded CCMC-6.9 self-assembled nanoparticles with a PTX-loading content of
30.4% in distilled water. The concentration of CCMC-6.9 was 0.5 mg ml−1.
The anticancer drug, paclitaxel (PTX), is known to have
the highly hydrophobic property [22], so that we hoped to
use CCMC-6.9 self-assembled nanoparticles as a carrier for
PTX to increase its aqueous solubility. The dialysis method
was used to prepare PTX-loaded CCMC-6.9 self-assembled
nanoparticles in this study. PTX dissolved in methanol
was first added to the nanoparticle solution, and then was
dialyzed against aqueous medium. In the dialysis process,
methanol was gradually removed, which resulted that PTX
spontaneously transferred from the aqueous medium into the
hydrophobic cores of CCMC-6.9 self-assembled nanoparticles
due to the driving force of hydrophobic interaction. TEM
image (figure 3(a)) shows that PTX-loaded CCMC-6.9 self-
assembled nanoparticles were almost spherical in shape.
However, compared with blank nanoparticles (figure 2), PTX-
loaded CCMC-6.9 self-assembled nanoparticles had a bumpier
surface, a larger size and a broader size distribution which
showed ‘two’ main peaks (figure 3(b)). We believed these
differences were due to the physical entrapment of PTX and
the agglomeration of nanoparticles during the drug loading
process.
The characteristics of PTX-loaded CCMC-6.9 self-
assembled nanoparticles are listed in table 1. The loading
content increased from 18.7% to 34.9% with the weight
ratio of drug to carrier increasing from 1/5 to 1/2 as
expected. However, the loading efficiency (92.8%–90.2%)
scarcely changed with the weight ratio ranging from 1/5 to
1/3, and then significantly decreased to 67.8% with the weight
ratio increasing to 1/2, which indicated that the ability of
CCMC-6.9 self-assembled nanoparticles to carry PTX reached
saturation. When PTX was entrapped in CCMC-6.9 self-
assembled nanoparticles, its maximum solubility in water
was about 0.7 mg ml−1, 100 times more than PTX water
solubility, which indicated that CCMC-6.9 self-assembled
nanoparticles could effectively solubilize PTX. Furthermore,
it is also shown from table 1 that the size of PTX-loaded
CCMC-6.9 self-assembled nanoparticles increased from 245.6
to 355.3 nm with the PTX-loading content increasing from
18.7% to 34.9%. Therefore, considering the size and the drug
loading property, we believed that 1/3 (drug/carrier) was the
optimal weight ratio to prepare PTX-loaded CCMC-6.9 self-
assembled nanoparticles.
4
Nanotechnology 19 (2008) 145101 Y-S Wang et al











1/5 245.6 ± 5.8 0.105 ± 0.053 18.7 ± 0.57 92.8 ± 1.60
1/4 279.9 ± 6.5 0.138 ± 0.017 23.6 ± 1.05 92.4 ± 2.57
1/3 305.3 ± 7.8 0.254 ± 0.079 30.4 ± 0.50 90.2 ± 1.45
1/2 355.3 ± 15.6 0.305 ± 0.059 34.9 ± 1.65 67.8 ± 4.55
a The weight ratio of PTX to CCMC-6.9 self-assembled nanoparticles.
b The size and size distribution (mean value ± standard deviation) of PTX-loaded CCMC-6.9
self-assembled nanoparticles determined by LLS three times.
c (Loading PTX/CCMC-6.9 self-assembled nanoparticles) ×100% (mean value ± standard
deviation) determined by UV method three times.
d (Loading PTX/total PTX) ×100% (mean value ± standard deviation) determined by
ultraviolet (UV) method three times.
Figure 4. PTX release profiles from PTX preparations at 37 ± 0.2 ◦C
in PBS solutions. PTX-Cre: PTX in the solution of Cremophor
EL/dehydrated alcohol; PTX-CCMC: PTX-loaded CCMC-6.9
self-assembled nanoparticles.
3.2. In vitro drug release study
PTX release behavior from CCMC-6.9 self-assembled
nanoparticles was studied in vitro by the dynamic dialysis
method proposed by Han [26] in PBS solution with the pH
values of 4.0, 7.2 and 9.0, respectively. PTX release from
the solution of Cremophor EL/dehydrated alcohol (50/50 v/v)
was also investigated as the control. The maximum
concentrations (4.0 μg ml−1) of PTX in PBS solutions in
the release experiments were less than the solubility (6–
10 μg ml−1) of PTX in these release media, so that the sink
condition for PTX could be assured. The cumulative PTX
release profiles are shown in figure 4. PTX rapidly released
from the solution of Cremophor EL/dehydrated alcohol in PBS
solution (pH = 7.2), and about 87.5% PTX was released in
12 h. However, during the same time period, only 32.0%
PTX released from CCMC-6.9 self-assembled nanoparticles
in PBS solution (pH = 7.2), and approximately 59.3% PTX
was released during 84 h, which suggested that CCMC-6.9
self-assembled nanoparticles had the potential as a sustained-
release carrier for PTX.
Furthermore, it is also shown from figure 4 that PTX
released from CCMC-6.9 self-assembled nanoparticles related
to the pH value of the release media. The PTX release
rate from CCMC-6.9 self-assembled nanoparticles in PBS
solution (pH = 7.2) was slightly slower than that in PBS
solution (pH = 4.0 or 9.0). We believed this was because
CCMC-6.9 was a novel ampholytic polyelectrolyte due to
the presence of carboxyl and amino groups in its molecule,
and its isoelectric point (pI) determined by the turbidimetry
method [28] was about 7.0. Therefore, when the pH value of
the PBS solution was 4.0 or 9.0, CCMC-6.9 self-assembled
nanoparticles absorbed water to swell due to the ionization
of amino groups or carboxyl groups, which resulting in
the increase of permeability of their non-covalently cross-
linked hydrogel structures, so that the PTX release rate
increased accordingly. The similar drug release mechanism
from other pH-sensitive hydrogel systems has already been
reported [11, 29, 30].
3.3. Tissue biodistribution study
Tissue biodistribution of PTX after intravenous administration
of CCMC-6.9 self-assembled nanoparticles to mice was
investigated with PTX-Cre as control. Mice showed no
obvious toxic reaction to administration of any formulation.
PTX concentration–time profiles in different tissues, including
plasma, heart, liver, spleen, lung and kidney, are shown
in figure 5. It was observed from the plasma PTX
concentration–time profile (figure 5(a)) that the time of
distribution phase was short and the concentration decreased
quickly in this phase, such as a 95% decrease of PTX
concentration during 2 h. Compared with PTX-Cre, a
97% decrease of PTX concentration in mice plasma during
2 h, there was a slightly decreased clearance of PTX,
but CCMC-6.9 self-assembled nanoparticles did not exhibit
obvious long-circulating properties in vivo, which was
different from other polymeric micelle formulations previously
reported [3, 4, 31–33]. This may be due to the structural
difference between CCMC-6.9 self-assembled nanoparticles
and other polymeric micelles. As shown in figure 6(a),
the amphiphilic block copolymer can form micelles with
a core–shell structure by self-assembly in aqueous media.
The hydrophilic shell of the micelle consists of flexible and
long-chain-length hydrophilic blocks, so that there is a big
space hindrance for the opsonin in the blood to adhere onto
the micelle surface, and thereby decrease the recognition
5
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Figure 5. PTX concentration–time profiles of PTX-loaded CCMC-6.9 self-assembled nanoparticles (–◦–) and PTX in a solution of
Cremophor EL/dehydrated alcohol (––) in mice plasma (a) and tissues of the heart (b), liver (c), spleen (d), lung (e) and kidney (f) (each
point represents the mean ± SD of 6 mice).
and subsequent phagocytosis by the mononuclear phagocytes,
which resulted in a long circulation time of micelles in
blood. However, a CCMC self-aggregated nanoparticle has
a poly-core model structure (figure 6(b)) which has been
reported before [11, 18]. The hydrophobic micro-domains
are formed by the association of cholesterol moieties and the
backbones of the O-carboxymethyl chitosan coil to form the
hydrophilic shells outside these hydrophobic micro-domains;
thus a minimal energy state is attained in aqueous media.
Furthermore, inter- and/or intramolecular hydrogen bonds
between polar groups of sugar monomers will stabilize the
poly-core structure of CCMC self-aggregated nanoparticles.
Thus, the hydrophilic backbones of O-carboxymethyl chitosan
tightly packed on the nanoparticle surface, so that there is
little space hindrance for the adherence of opsonin, and for the
recognition and phagocytosis by the mononuclear phagocytes,
which resulted in the rapid decrease of PTX concentration in
the plasma.
The AUC of two PTX preparations in different tissues
were calculated by the trapezoid method. As shown in
Figure 6. Schematic representations of self-assembly micelle of
amphiphilic block copolymer (a) and CCMC self-aggregated
nanoparticle (b) [18].
figure 7, the order of AUC from highest to lowest for
PTX-loaded CCMC-6.9 self-assembled nanoparticles was
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Figure 7. Comparative tissue distribution (AUC, 0–12 h) of PTX
formulations. PTX-Cre: PTX in a solution of Cremophor
EL/dehydrated alcohol; PTX-CCMC: PTX-loaded CCMC-6.9
self-assembled nanoparticles. Data represent the mean ± SD; paired
t-test, ∗ P < 0.05.
liver > spleen > lung > kidney > heart > plasma, similar to
the corresponding order for the control. However, the PTX
AUC of CCMC-6.9 nanoparticles was significantly higher
in plasma, liver and spleen, but lower in heart and kidney,
compared to the control. We believed that the higher PTX
AUC in plasma than the control in tissue biodistribution was
due to the solubilizing effect of CCMC-6.9 self-assembled
nanoparticles on PTX. The PTX AUC of CCMC-6.9 self-
assembled nanoparticles in liver was 137.9 μg h g−1, a 91%
increase compared to the PTX AUC of control (71.9 μg h g−1),
and more than 10% PTX remained in the liver after 12 h, which
indicated that CCMC-6.9 self-assembled nanoparticles showed
a high targeting efficiency and a long retention time in liver.
This result was consistent with the study reported by Huo [25].
Moreover, it is well known that the adverse side effects of
PTX in clinical practice mainly include myelosuppression,
cardiotoxicity, renal toxicity and some allergic reactions, and
therefore the lower PTX AUC in heart and kidney than the
control in tissue biodistribution will be advantageous to reduce
the toxicity of PTX.
4. Conclusions
In this study, CCMC-6.9 self-assembled nanoparticles were
prepared and their potential for being used as the carrier
for PTX was systemically investigated in vitro and in vivo.
CCMC-6.9 self-assembled nanoparticles efficiently loaded
PTX and significantly enhanced PTX solubility in water.
The release in vitro of PTX from CCMC-6.9 self-assembled
nanoparticles was sensitive to the pH of the release media, and
the release rate was slower than that of PTX in the solution
of Cremophor EL/dehydrated alcohol (PTX-Cre). The tissue
distribution of PTX entrapped in CCMC-6.9 self-aggregated
nanoparticles after intravenous injection into mice changed
compared to PTX-Cre. The uptake of PTX significantly
increased in plasma and liver, but decreased in heart and
kidney. It is concluded that CCMC-6.9 self-assembled
nanoparticles can effectively solubilize PTX and modify the
biodistribution of PTX, which is advantageous to enhance the
therapeutic index and reduce the toxicity of PTX. A further
study on the anti-tumor effects of PTX-loaded CCMC-6.9 self-
assembled nanoparticles is in progress now.
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